Your browser doesn't support javascript.
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.
Pinato, David J; Lee, Alvin J X; Biello, Federica; Seguí, Elia; Aguilar-Company, Juan; Carbó, Anna; Bruna, Riccardo; Bower, Mark; Rizzo, Gianpiero; Benafif, Sarah; Carmona, Carme; Chopra, Neha; Cruz, Claudia Andrea; D'Avanzo, Francesca; Evans, Joanne S; Galazi, Myria; Garcia-Fructuoso, Isabel; Dalla Pria, Alessia; Newsom-Davis, Thomas; Ottaviani, Diego; Patriarca, Andrea; Reyes, Roxana; Sharkey, Rachel; Sng, Christopher C T; Wong, Yien Ning Sophia; Ferrante, Daniela; Scotti, Lorenza; Avanzi, Gian Carlo; Bellan, Mattia; Castello, Luigi Mario; Marco-Hernández, Javier; Mollà, Meritxell; Pirisi, Mario; Ruiz-Camps, Isabel; Sainaghi, Pier Paolo; Gaidano, Gianluca; Brunet, Joan; Tabernero, Josep; Prat, Aleix; Gennari, Alessandra.
  • Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0HS, UK.
  • Lee AJX; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • Biello F; Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Seguí E; Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain.
  • Aguilar-Company J; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Carbó A; Department of Infectious Diseases, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Bruna R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain.
  • Bower M; Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Rizzo G; Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London SW109NH, UK.
  • Benafif S; Department of Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
  • Carmona C; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • Chopra N; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain.
  • Cruz CA; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • D'Avanzo F; Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain.
  • Evans JS; Department of Translational Medicine, Division of Oncology, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Galazi M; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London W12 0HS, UK.
  • Garcia-Fructuoso I; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • Dalla Pria A; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain.
  • Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London SW109NH, UK.
  • Ottaviani D; Department of Oncology and National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London SW109NH, UK.
  • Patriarca A; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • Reyes R; Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Sharkey R; Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain.
  • Sng CCT; Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Wong YNS; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • Ferrante D; Department of Oncology, University College London Hospitals, London NW1 2PG, UK.
  • Scotti L; Department of Translational Medicine, Unit of Cancer Epidemiology, CPO-Piemonte, University of Piemonte Orientale, 28100 Novara, Italy.
  • Avanzi GC; Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Bellan M; Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Castello LM; Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Marco-Hernández J; Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Mollà M; Department of Internal Medicine, Hospital Clinic, 08035 Barcelona, Spain.
  • Pirisi M; Department of Radiation Oncology, Hospital Clinic, 08035 Barcelona, Spain.
  • Ruiz-Camps I; Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Sainaghi PP; Department of Infectious Diseases, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Gaidano G; Department of Translational Medicine, Divisions of Internal and Emergency Medicine, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Brunet J; Department of Translational Medicine, Division of Haematology, University of Piemonte Orientale and Maggiore della Carita' Hospital, 28100 Novara, Italy.
  • Tabernero J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, 17007 Girona, Spain.
  • Prat A; Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  • Gennari A; Department of Medical Oncology, Hospital Clinic, 08036 Barcelona, Spain.
Cancers (Basel) ; 12(7)2020 Jul 08.
Article in English | MEDLINE | ID: covidwho-639970
ABSTRACT
We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged > 18 (mean = 69) and diagnosed with COVID-19 between February 26th and April 1st, 2020. A total of 127 (62%) were male, 184 (91%) had a diagnosis of solid malignancy, and 103 (51%) had non-metastatic disease. A total of 161 (79%) had > 1 co-morbidity. A total of 141 (69%) patients had > 1 COVID-19 complication. A total of 36 (19%) were escalated to high-dependency or intensive care. A total of 59 (29%) died, 53 (26%) were discharged, and 92 (45%) were in-hospital survivors. Mortality was higher in patients aged > 65 (36% versus 16%), in those with > 2 co-morbidities (40% versus 18%) and developing > 1 complication from COVID-19 (38% versus 4%, p = 0.004). Multi-variable analyses confirmed age > 65 and > 2 co-morbidities to predict for patient mortality independent of tumor stage, active malignancy, or anticancer therapy. During the early outbreak of SARS-CoV-2 infection in Europe co-morbid burden and advancing age predicted for adverse disease course in cancer patients. The ongoing OnCovid study will allow us to compare risks and outcomes in cancer patients between the initial and later stages of the COVID-19 pandemic.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2020 Document Type: Article Affiliation country: Cancers12071841

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Year: 2020 Document Type: Article Affiliation country: Cancers12071841